CA2978808A1 - Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for il15r.alpha. and therapeutic uses thereof - Google Patents

Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for il15r.alpha. and therapeutic uses thereof Download PDF

Info

Publication number
CA2978808A1
CA2978808A1 CA2978808A CA2978808A CA2978808A1 CA 2978808 A1 CA2978808 A1 CA 2978808A1 CA 2978808 A CA2978808 A CA 2978808A CA 2978808 A CA2978808 A CA 2978808A CA 2978808 A1 CA2978808 A1 CA 2978808A1
Authority
CA
Canada
Prior art keywords
fusion protein
cancer
protein
binding
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2978808A
Other languages
English (en)
French (fr)
Inventor
Jung GUNDRAM
Helmut Salih
Cornelia Lindner
Berit Lochmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52629425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2978808(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of CA2978808A1 publication Critical patent/CA2978808A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2978808A 2015-03-06 2016-03-07 Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for il15r.alpha. and therapeutic uses thereof Pending CA2978808A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15157911.7A EP3064507A1 (en) 2015-03-06 2015-03-06 Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
EP15157911.7 2015-03-06
PCT/EP2016/054729 WO2016142314A1 (en) 2015-03-06 2016-03-07 FUSION PROTEINS COMPRISING A BINDING PROTEIN AND AN INTERLEUKIN-15 POLYPEPTIDE HAVING A REDUCED AFFINITY FOR IL15Ra AND THERAPEUTIC USES THEREOF

Publications (1)

Publication Number Publication Date
CA2978808A1 true CA2978808A1 (en) 2016-09-15

Family

ID=52629425

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2978808A Pending CA2978808A1 (en) 2015-03-06 2016-03-07 Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for il15r.alpha. and therapeutic uses thereof

Country Status (16)

Country Link
US (3) US10906952B2 (cg-RX-API-DMAC7.html)
EP (2) EP3064507A1 (cg-RX-API-DMAC7.html)
JP (1) JP6757338B2 (cg-RX-API-DMAC7.html)
CN (1) CN107636015A (cg-RX-API-DMAC7.html)
BR (1) BR112017018975A2 (cg-RX-API-DMAC7.html)
CA (1) CA2978808A1 (cg-RX-API-DMAC7.html)
CY (1) CY1122494T1 (cg-RX-API-DMAC7.html)
DK (1) DK3265478T3 (cg-RX-API-DMAC7.html)
ES (1) ES2763598T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20192190T1 (cg-RX-API-DMAC7.html)
HU (1) HUE047818T2 (cg-RX-API-DMAC7.html)
PL (1) PL3265478T3 (cg-RX-API-DMAC7.html)
PT (1) PT3265478T (cg-RX-API-DMAC7.html)
RS (1) RS59658B1 (cg-RX-API-DMAC7.html)
SI (1) SI3265478T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016142314A1 (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
EP3064507A1 (en) * 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
CN106380521B (zh) 2015-07-02 2020-12-29 博际生物医药科技(杭州)有限公司 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
AU2017283480A1 (en) 2016-06-13 2019-01-24 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
PE20240950A1 (es) * 2016-10-14 2024-05-06 Xencor Inc PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN117384929A (zh) 2017-03-27 2024-01-12 新加坡国立大学 一种编码由细胞表达的嵌合受体的多核苷酸
RU2019128544A (ru) 2017-03-27 2021-04-28 Нэшнл Юниверсити Оф Сингапур Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров
UA125700C2 (uk) 2017-04-03 2022-05-18 Ф. Хоффманн-Ля Рош Аг Імунокон'югати антитіла до pd-1 з мутантом il-2
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
KR20250056192A (ko) 2017-08-07 2025-04-25 더 리전트 오브 더 유니버시티 오브 캘리포니아 안전한 세포 치료제를 생성하기 위한 플랫폼
EP3678701A4 (en) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. THERAPEUTIC PROTEIN COMPOSITIONS AND METHODS FOR PREPARING AND USING THE SAME
CA3076014A1 (en) * 2017-09-29 2019-04-04 Nantcell, Inc. Antigenic proteins and methods therefor
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
TWI834636B (zh) * 2018-02-26 2024-03-11 美商欣爍克斯公司 Il-15結合物及其用途
PE20201342A1 (es) * 2018-02-28 2020-11-25 Pfizer Variantes de il-15 y usos de las mismas
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
CN112867734A (zh) 2018-04-18 2021-05-28 Xencor股份有限公司 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
IL278090B2 (en) 2018-04-18 2024-07-01 Xencor Inc Il-15/il-15rα heterodimeric fc fusion proteins and uses thereof
WO2019246142A1 (en) * 2018-06-18 2019-12-26 Haiming Chen Soluble bispecific fusion proteins for cancer immunotherapy
CN112368015B (zh) * 2018-06-18 2025-04-29 安维达生物科技公司 细胞因子融合蛋白及其用途
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
EP3847196A4 (en) * 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
CN109207430A (zh) * 2018-09-25 2019-01-15 华东师范大学 一种嵌合抗原受体nk细胞及其制备方法和应用
JP6935383B2 (ja) * 2018-09-27 2021-09-15 公益財団法人実験動物中央研究所 免疫不全マウス
KR20250154552A (ko) 2018-09-27 2025-10-28 실리오 디벨럽먼트, 인크. 마스킹된 사이토카인 폴리펩타이드
MA53862A (fr) 2018-10-12 2022-01-19 Xencor Inc Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci
EP3897853A1 (en) 2018-12-20 2021-10-27 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
US20220241375A1 (en) 2019-05-20 2022-08-04 Cytune Pharma Il-2/il-15r beta gamma agonist dosing regimens for treating cancer or infectious diseases
CN114286683B (zh) * 2019-07-17 2024-10-01 新加坡国立大学 由免疫细胞合成和分泌的功能性结合物
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
CN111690068B (zh) * 2019-11-13 2022-04-19 中国科学技术大学 一种IL-15/SuIL-15Rα-dFc-γ4复合体蛋白及其构造方法、应用
EP3822288A1 (en) * 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
CN114761433B (zh) * 2019-12-11 2025-07-29 上海复宏汉霖生物技术股份有限公司 一种抗Claudin18.2单克隆抗体、其制备方法及用途
CN116406380A (zh) * 2020-09-17 2023-07-07 上海霖羲致企业管理有限公司 双特异性重组蛋白及其用途
AU2021367887A1 (en) 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
MX2023004880A (es) 2020-10-26 2023-05-11 Cytune Pharma AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA.
KR20230113581A (ko) 2020-11-25 2023-07-31 실리오 디벨럽먼트, 인크. 종양 특이적 절단성 링커
CN117186227A (zh) * 2020-12-23 2023-12-08 瑞泽恩制药公司 编码锚修饰的抗体的核酸以及其用途
BR112023027305A2 (pt) 2021-06-23 2024-03-12 Cytune Pharma Variante de interleucina-15, conjugado, proteína de fusão, ácido nucleico, vetor, célula hospedeira e composição farmacêutica
WO2023280287A1 (en) * 2021-07-09 2023-01-12 Nanjing Legend Biotech Co., Ltd. Interleukin-15 variants and uses thereof
KR20240043797A (ko) 2021-08-13 2024-04-03 싸이튠 파마 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합
CN113956346B (zh) * 2021-10-26 2024-03-01 西安龙腾景云生物科技有限公司 一种重组白介素-15变体
CN115141283A (zh) * 2022-03-10 2022-10-04 厦门柏慈生物科技有限公司 一种融合蛋白、制备方法及其应用
WO2024085166A1 (ja) * 2022-10-19 2024-04-25 アステラス製薬株式会社 がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用
CN120693344A (zh) * 2023-02-14 2025-09-23 德国癌症研究公共权益基金会 具有改善的特性的il-15融合蛋白
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
WO2024215989A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS
WO2025147512A1 (en) * 2024-01-02 2025-07-10 Eli Lilly And Company Immunogenicity assessment platform for biotherapeutic proteins
WO2025222129A2 (en) * 2024-04-19 2025-10-23 Mozart Therapeutics, Inc. Engineered cytokines and targeted cytokine delivery

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2004106381A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
EP1658308A1 (en) 2003-08-25 2006-05-24 Pieris ProteoLab AG Muteins of a bilin-binding protein with affinity for a given target
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
ATE516305T1 (de) * 2004-02-27 2011-07-15 Inst Nat Sante Rech Med Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
MX2007006832A (es) 2004-12-13 2007-08-07 Cytos Biotechnology Ag Arreglos de antigeno interleucina 15 y usos de los mismos.
MX2009001203A (es) 2006-08-01 2009-06-01 Pieris Ag Muteinas de lipocalina lacrimosa y metodos para obtener las mismas.
JP5501222B2 (ja) * 2007-05-11 2014-05-21 アルター・バイオサイエンス・コーポレーション 融合分子及びｉｌ−１５変異体
US20120196310A1 (en) 2009-10-02 2012-08-02 Christiane Jaeger A-fucosylation detection in antibodies
DK2990798T3 (da) 2009-12-07 2019-12-02 Pieris Pharmaceuticals Gmbh Muteiner af human lipocalin 2 (lcn2, hngal) med affinitet for et specifikt mål
EP2918607B1 (en) 2010-09-21 2017-11-08 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
CA2859767C (en) 2011-12-19 2018-09-11 Synimmune Gmbh Bispecific antibody molecule and use thereof for treatment of proliferative disease
US10202433B2 (en) 2013-06-27 2019-02-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) IL-15 mutant polypeptides as IL-15 antagonists and encoding nucleic acids
EP3064507A1 (en) * 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
PE20201342A1 (es) 2018-02-28 2020-11-25 Pfizer Variantes de il-15 y usos de las mismas

Also Published As

Publication number Publication date
JP6757338B2 (ja) 2020-09-16
RS59658B1 (sr) 2020-01-31
PL3265478T3 (pl) 2020-03-31
DK3265478T3 (da) 2019-12-16
HRP20192190T1 (hr) 2020-02-21
CY1122494T1 (el) 2021-01-27
PT3265478T (pt) 2020-01-08
US20210163564A1 (en) 2021-06-03
SI3265478T1 (sl) 2020-01-31
ES2763598T3 (es) 2020-05-29
US20220324931A1 (en) 2022-10-13
US20180044391A1 (en) 2018-02-15
HUE047818T2 (hu) 2020-05-28
WO2016142314A1 (en) 2016-09-15
US10906952B2 (en) 2021-02-02
EP3265478B1 (en) 2019-09-11
BR112017018975A2 (pt) 2018-04-17
CN107636015A (zh) 2018-01-26
JP2018512168A (ja) 2018-05-17
EP3265478A1 (en) 2018-01-10
EP3064507A1 (en) 2016-09-07

Similar Documents

Publication Publication Date Title
US20220324931A1 (en) FUSION PROTEINS COMPRISING A BINDING PROTEIN AND AN INTERLEUKIN-15 POLYPEPTIDE HAVING A REDUCED AFFINITY FOR IL15Ra AND THERAPEUTIC USES THEREOF
JP7153626B2 (ja) 抗ヒト４－１ｂｂ抗体およびその使用
EP3250611B1 (en) Car t-cells recognizing cancer-specific il 13r-alpha2
US12378295B2 (en) Rationally designed protein compositions
JP2022523722A (ja) 複数ドメイン結合性分子
CN107108748A (zh) SIRPα免疫球蛋白融合蛋白
JP2022528030A (ja) 多機能性融合タンパク質及びその使用
TW201831517A (zh) 靶向組織蛋白h3肽/mhc複合體之構築體及其用途
WO2023006082A1 (zh) 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
US20240294594A1 (en) Interleukin-15 based immunocytokines
JP2024543152A (ja) 改善された抗原結合受容体
CN117412768A (zh) 抗体-nkg2d配体结构域融合蛋白
WO2022090556A1 (en) Bcma/taci antigen-binding molecules
US20210277139A1 (en) Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof
TW202204391A (zh) 一種SIRPα-Fc融合蛋白
CA3220418A1 (en) Interleukin 15 variants
CN120693344A (zh) 具有改善的特性的il-15融合蛋白
CN119731199A (zh) 工程化的白细胞介素-2受体β降低结合的激动剂
HK40088090A (zh) 改善的抗原结合受体

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908